文献速递间质性肺疾病

肺朗格汉斯细胞组织细胞增生症患者肺移植的临床结局与生存分析

Clinical outcomes and survival following lung transplantation in patients with pulmonary Langerhans cell histiocytosis.
PubMed 文献 · Respirology · 2019-08-12

该研究基于美国器官获取与移植网络数据库,分析了1987年10月至2017年6月期间接受肺移植的87例成人肺朗格汉斯细胞组织细胞增生症(PLCH)患者。结果显示,PLCH患者肺移植后中位生存期与其他肺疾病患者相当(5.1年 vs 5.5年,P=0.76),女性性别、移植前血清胆红素和肌酐水平与移植后死亡率独立相关。

要点

  • PLCH患者肺移植后中位生存期与其他肺疾病患者无显著差异。
  • 女性性别与较低的移植后死亡风险独立相关(HR 0.40)。
  • 移植前血清胆红素和肌酐升高与移植后死亡风险增加独立相关。

核心结论

  • PLCH患者肺移植后生存率与其他肺疾病患者相似,且受患者性别显著影响。

研究设计与样本

  • 回顾性队列研究,查询美国器官获取与移植网络数据库,纳入1987年10月至2017年6月接受肺移植的87例成人PLCH患者。

主要发现

  • PLCH患者肺移植中位生存期为5.1年,其他肺疾病患者为5.5年(P=0.76)。
  • PLCH患者移植后1、3、5、10年生存率分别为85%、65%、49%和22%。
  • 女性性别(HR 0.40,95%CI 0.22-0.72)、移植前血清胆红素(HR 1.66,95%CI 1.23-2.26)和血清肌酐(HR 4.03,95%CI 1.01-14.76)与移植后死亡率独立相关。

临床怎么用

  • 对于符合条件的PLCH患者,肺移植可作为治疗选择,其生存结局与其他肺疾病患者相当。
  • 移植前应评估血清胆红素和肌酐水平,并关注性别对预后的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Disease-specific outcomes following lung transplantation (LT) in patients with pulmonary Langerhans cell histiocytosis (PLCH) are not well established. We queried the Organ Procurement and Transplantation Network database to identify adult PLCH patients who had undergone LT in the United States. METHODS: Overall survival data were analysed with Kaplan-Meier curves. Cox proportional hazard model was used to determine the effect of demographic, clinical and physiological variables on post-transplant survival. RESULTS: A total of 87 patients with PLCH underwent LT in the United States between October 1987 and June 2017, accounting for 0.25% of the total LT during this period. The mean age at LT for PLCH patients was 49 years (range: 19-67 years), with a near equal gender distribution. Bilateral sequential LT was performed in 71 patients (82%). Pulmonary hypertension was present in 85% of patients, with a mean pulmonary artery pressure of 38.5 ± 14.1 mm Hg. The mean pre-transplant forced expiratory volume in 1 s (FEV1 ) was 41 ± 21% predicted and the mean 6-min walk distance was 221 ± 111 m. Median post-LT survival for PLCH patients was comparable to patients with other lung diseases (5.1 vs 5.5 years, P = 0.76). The actuarial Kaplan-Meier post-LT survival for PLCH patients was 85%, 65%, 49% and 22% at 1, 3, 5 and 10 years, respectively. Female sex (hazard ratio (HR): 0.40, 95% CI: 0.22-0.72), pre-transplant serum bilirubin (HR: 1.66, 95% CI: 1.23-2.26) and serum creatinine (HR: 4.03, 95% CI: 1.01-14.76) were independently associated with post-LT mortality in our cohort. CONCLUSION: Post-LT survival in patients with PLCH is similar to patients with other lung diseases and is significantly affected by patient gender.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Wajda N, Zhu Z, Jandarov R, et al. Clinical outcomes and survival following lung transplantation in patients with pulmonary Langerhans cell histiocytosis. Respirology. 2019. PMID: 31407478. doi:10.1111/resp.13671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。